Bowel Cancer Australia recently announced a team led by Professor Michael Samuel as the successful applicant for a three-year $600k early-onset bowel cancer research project through the 2023 round of Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS).
According to Bowel Cancer Australia, bowel cancer in the under fifties is trending upward, with 1-in-9 new bowel cancer cases now occurring in people under age 50, and presentation with metastatic disease more frequent in this demographic. Rates in the over fifties have stabilised or are declining.
Rho-associated kinase or ROCK, is an enzyme (protein) found in everyone, and it controls the shape and movement of cells within the body.
The way in which cancer cells communicate with normal cells in their environment via ROCK has been discovered to drive disease progression (invasion, metastasis, and recurrence). This understanding has revealed that blocking cancers from hijacking normal cells in this way could be a new way to target the disease.
Professor Samuel of the Centre for Cancer Biology (an alliance between the University of South Australia and SA Pathology) and the Basil Hetzel Institute for Translational Health Research will investigate ROCK-induced early-onset bowel cancer progression.
“People diagnosed with early-onset bowel cancer have a 50% chance that their cancer will recur or spread to other organs following initial intervention (e.g. surgery to remove the primary cancer), compared to around 30% in people diagnosed with late-onset bowel cancer,” says Professor Samuel.
“We have evidence that ROCK activity in bowel cancers drives this process by influencing how cancers communicate with their environment. Our project will investigate how this happens. We will also study whether certain effects of ROCK activation in early-onset bowel cancers can help us predict whose cancers will recur and whose will not,” he continues.
“In a practical sense, this could help us use targeted therapies that block cancer cells from communicating with their environment, in people who are most likely to experience recurrence of their cancer. It could also help us minimise the use of debilitating chemotherapies,” he adds.
The research team, which includes clinicians from the Central Adelaide Local Health Network, will also be examining whether proteins that interact with ROCK cause early-onset bowel cancer progression, and if they do, targeting these proteins would be a way of stopping ROCK from accelerating tumour growth.
Source: Bowel Cancer Australia
-
Space Health & Medicine on Australia’s Clinical Launchpad
Professor Smart is a veteran, medical doctor, health leader, aerospace medicine specialist, and retired Royal Australian Air Force (RAAF) senior officer. She is currently at the Professor, Military and Aerospace Medicine at the Australian National University (ANU), and serves as the Interim Director of the ANU Defence Institute, and as a Mission Specialist at the ANU Institute for Space. She previously served as the University’s COVID-19 Public Health Lead from 2020 to 2022.
-
Australia’s Nursing Crisis Snapshot
“Nursing, already under pressure, is reaching breaking point due to the pressures of COVID-19 and a disjointed healthcare system, including the acute, primary and aged care sectors”, says Kylie Ward, Australian College of Nursing CEO adding, “We must act now to protect our nurses and healthcare; the time has come for a national reckoning on nursing in Australia.”
Australian nurses cannot continue to work under the extreme pressure they are currently operating under – the impacts are mounting.
The almost 400,000 Australian nurses are a constant presence in every one of our major life milestones, national emergencies and global crises. The nurse of today holds a science degree, possesses highly technical training, valuable medical opinions, front-row expertise, is an effective trainer, and is skilled in population and systemic thinking. But the pandemic is inflicting a major emotional and physical toll on nurses.
In this “Perspectives” special, Australian Health Journal spoke with 4 nurses on the challenges they or nurses in their circle have experienced, the key issues as well some of the opportunities. These nurses come from national leadership & policy, large scale workforce management, a final year student completing over a year on placement across 6 Melbourne Hospitals and a NSW based ICU nurse stranded in Mexico, unable to return to a critical role in nursing to an already strained team due to incoming quotas.
While the issues are challenging, there are strategies that can be put into place to ease the pressure, to support nurses, and nursing care in Australia. These are discussed by the the 4 nurses.
– Adjunct Professor Kylie Ward FACN CEO, Australian College of Nursing
– Adjunct Professor Alanna Geary FACN ACN Chair of Workforce Sustainability Policy Chapter & Chief Nursing & Midwifery Officer, Metro North Health
– Natalie Reyes, NSW based ICU Nurse Currently stranded in Mexico
– Hayley Pollock, Final Year Bachelor of Nursing Student & ACN Emerging Nurse Leader
-
Continuing education program leads to better conversations
Medicines Australia’s Continuing Education Program (CEP) is designed to educate medical representatives to a recognised industry standard. Dr Tristan Ling, CEP Academic Lead and Project Manager at the College of Health and Medicine, University of Tasmania talks about the 900 students that come through the program each year.
The CEP is primarily directed at medical representatives working within the prescription medicines industry, but is also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative. It is also available to personnel working for organisations interacting with the pharmaceutical industry.
